Emergent BioSolutions (EBS) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Q32 Bio (QTTB) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 317.0% versus a loss of 49.7%. Over five years, EBS leads with a -88.6% price change compared with -91.1% for QTTB. Emergent BioSolutions is the larger company by market cap ($259.6 million vs $249.6 million), about 1.0 times the size.
Q32 Bio converts more of its revenue into profit, with a net margin of 55.5% versus 7.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | QTTB |
|---|---|---|
| Share price | $5.05 | $8.34 |
| Market cap | $259.65M | $249.57M |
| 1-day change | -1.94% | -1.65% |
| YTD return | -59.14% | +151.20% |
| 1-year return | -49.70% | +317.00% |
| 5-year return | -88.58% | -91.12% |
| P/E ratio (TTM) | — | 2.32 |
| Forward P/E | 4.83 | — |
| EPS (TTM) | $-5.00 | $3.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $742.90M | $53.74M |
| Revenue growth (YoY) | -28.81% | — |
| Net income (latest FY) | $52.60M | $29.82M |
| Gross margin | 56.09% | — |
| Operating margin | 13.47% | 31.45% |
| Net margin | 7.08% | 55.49% |
| 52-week high | $14.06 | $23.57 |
| 52-week low | $4.36 | $1.98 |
| Distance from 52-week high | -64.08% | -64.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +98.02% | +375.66% |
| Average volume | 1.11M | 692.58K |
| Shares outstanding | 51.42M | 29.92M |
| Employees | 900 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed EBS by 366.7 percentage points over the past year.
- Q32 Bio is more profitable, keeping 55.5 cents of every revenue dollar as net income versus 7.1 cents for Emergent BioSolutions.
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
EBS vs QTTB FAQ
Which is bigger, Emergent BioSolutions or Q32 Bio?
Emergent BioSolutions (EBS) is larger, with a market capitalization of $259.65M compared with $249.57M for Q32 Bio (QTTB).
Which stock has performed better over the past year, EBS or QTTB?
QTTB returned +317.00% over the past 12 months, compared with -49.70% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.